Actinium Pharmaceuticals Receives Two Patent Allowances Spanning Its Actimab-A and Iomab-ACT Programs
Rhea-AI Summary
Actinium Pharmaceuticals (NYSE American: ATNM) received two Canadian patent allowances covering its Actimab-A and Iomab-ACT programs. These patents extend protection for Actimab-A plus CLAG-M in AML and CD45-targeted conditioning for gene-edited cell therapies, reinforcing a global estate of about 250 patents and applications, with Canadian terms into 2038 and 2039.
AI-generated analysis. Not financial advice.
Positive
- Two Canadian patent allowances expand protection for Actimab-A and Iomab-ACT
- Global intellectual property estate reinforced to about 250 patents and applications
- Actimab-A + CLAG-M AML patent term in Canada extends into January 2039
- Iomab-ACT gene-edited therapy conditioning patent term in Canada extends into October 2038
- Canadian patents complement existing IP in Japan, the United States, Europe and China applications
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
ATNM gained 9.57% while peers were mixed: GNTA up 4.78%, PDSB flat, and PYPD, VTVT, CUE down between 0.45% and 4.7%, pointing to a stock-specific move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| May 06 | Conference data update | Positive | -1.6% | SNMMI 2026 presentations highlighting ATNM-400 and radiochemistry optimization. |
| Apr 22 | Preclinical efficacy data | Positive | -10.9% | Compelling pan-tumor ATNM-400 data across multiple cancer models at AACR. |
| Apr 22 | Mechanism of action data | Positive | -10.9% | Actimab-A transcriptional reprogramming data supporting mutation-agnostic AML activity. |
| Apr 06 | Conference preview | Positive | +11.2% | Announcement of upcoming AACR abstracts for ATNM-400 and Actimab-A. |
| Feb 17 | Conference participation | Positive | -2.7% | Notice of two AACR 2026 abstracts focused on radiotheranostic platforms. |
Recent positive R&D and conference news often saw negative price reactions, with only one out of five events showing a positive move.
Over the past months, Actinium has focused newsflow on its radiotherapy pipeline, highlighting ATNM-400 pan-tumor activity and Actimab-A’s differentiated AML mechanism at AACR 2026 and related meetings. Despite generally positive scientific updates, shares often declined afterward, including moves of -10.86% on April 22, 2026. One earlier AACR-related announcement on April 6, 2026 coincided with an 11.18% gain. Today’s patent allowances extend protection around Actimab-A and Iomab-ACT, reinforcing these same strategic franchises.
Market Pulse Summary
This announcement strengthened Actinium’s intellectual property around two key franchises, adding Canadian patent allowances for Actimab-A combinations in AML and Iomab-ACT conditioning for gene-edited cell-based therapies, with terms running into 2038 and 2039. These patents contribute to an estate of approximately 250 issued and pending patents and applications worldwide. Against a backdrop of recent SEC filings highlighting net losses and listing-compliance challenges, investors may focus on how this IP supports long-term pipeline value.
Key Terms
hematologic malignancies medical
acute myeloid leukemia medical
cd45 medical
AI-generated analysis. Not financial advice.
- Together the allowances deepen protection across two priority franchises and reinforce a patent estate of approximately 250 issued and pending patents and patent applications worldwide
The Notices of Allowance follow examination by CIPO, with issuance of the patents expected in the ordinary course. The allowances deepen Actinium's intellectual property protection across two of its priority franchises and reinforce a global patent estate of approximately 250 issued and pending patents and patent applications.
"These two allowances reflect the breadth and depth of the innovation across our radiotherapy platform and our commitment to protecting it in every key market," said Adeela Kamal, Ph.D., EVP-R&D of Actinium Pharmaceuticals. "Securing coverage for both our Actimab-A CLAG-M combination in AML and our Iomab-ACT conditioning approach for gene-edited cell-based therapies underscores the strength of our science and the durability of the franchises we are building. We will continue to expand and defend our intellectual property worldwide as we advance these programs toward patients."
Actimab-A + CLAG-M Combination for AML
The allowed application covers the use of Actimab-A in combination with the CLAG-M chemotherapy regimen for the treatment of AML. Actimab-A is one of Actinium's most advanced clinical-stage candidates and may serve as a therapeutic backbone for myeloid malignancies. The Canadian allowance complements a counterpart patent already granted in
Iomab-ACT for Gene-Edited Cell-Based Therapies
The allowed application covers Actinium's targeted CD45 conditioning approach used to prepare patients for gene-edited cell-based therapies. Iomab-ACT is designed as a targeted conditioning agent intended to enable adoptive cell therapies. The Canadian allowance builds on a patent already granted in
About Actinium Pharmaceuticals, Inc.
Actinium is a pioneer in targeted radiotherapies designed to improve outcomes for patients with cancer. The company employs a biology-driven approach to develop differentiated radiopharmaceuticals for solid tumors and hematologic malignancies. Its mission is to transform cancer treatment through innovative radioconjugates that maximize therapeutic efficacy while minimizing toxicity to healthy tissue by combining expertise in tumor biology, translational medicine, and radiochemistry. Since inception, Actinium has focused on developing innovative radiotherapies. Its pipeline reflects this strategy across three areas: (1) solid tumor therapeutics including ATNM-400 and Actimab-A with pan-tumor potential; (2) Actimab-A as a therapeutic backbone for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) in collaboration with the National Cancer Institute (NCI); and (3) targeted conditioning agents including Iomab-B for bone marrow transplant and Iomab-ACT for adoptive cell therapy conditioning. ATNM-400 targets a novel antigen distinct from PSMA and has demonstrated preclinical activity across metastatic castration-resistant prostate cancer (mCRPC), non-small cell lung cancer (NSCLC), and breast cancer. Actimab-A has shown improved survival in relapsed/refractory AML with CLAG-M and is advancing toward a Phase 2/3 trial, with additional development ongoing through a CRADA with the NCI. Actinium is also advancing preclinical solid tumor programs and holds ~250 patents and patent applications, including intellectual property related to cyclotron-based production of Ac-225. For more information, please visit www.actiniumpharma.com.
Forward-Looking Statements
This press release may contain projections or other "forward-looking statements" within the meaning of the "safe-harbor" provisions of the private securities litigation reform act of 1995 regarding future events or the future financial performance of the Company which the Company undertakes no obligation to update. These statements, including statements as related to regaining compliance with the rules of the NYSE American and submission of a compliance plan, are based on management's current expectations and are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with preliminary study results varying from final results, estimates of potential markets for drugs under development, clinical trials, actions by the FDA and other governmental agencies, regulatory clearances, responses to regulatory matters, the market demand for and acceptance of Actinium's products and services, performance of clinical research organizations and other risks detailed from time to time in Actinium's filings with the Securities and Exchange Commission (the "SEC"), including without limitation its most recent annual report on form 10-K, subsequent quarterly reports on Forms 10-Q and Forms 8-K, each as amended and supplemented from time to time.
Investors: investorrelations@actiniumpharma.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/actinium-pharmaceuticals-receives-two-patent-allowances-spanning-its-actimab-a-and-iomab-act-programs-302786081.html
SOURCE Actinium Pharmaceuticals, Inc.